Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.

Marvaso, G.; Francolini, G.; Achard, V.; Gomez-Iturriaga, A.; Slevin, F.; Zilli, T.; Ost, P.

Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.

All Authors

Marvaso, G.

Francolini, G.

Achard, V.

Gomez-Iturriaga, A.

Slevin, F.

Zilli, T.

Ost, P.

LTHT Author

Slevin, Finbar

LTHT Department

Oncology
Leeds Cancer Centre

Publication Date

2026

Item Type

Editorial

Abstract

Results from the EMBARK trial reshape the treatment paradigm for high-risk biochemical recurrence of prostate cancer. EMBARK data support the use of androgen receptor pathway inhibitors combined with metastasis-directed therapy in a personalized, multidisciplinary care approach for this subset of patients.